terrific in every respect
terrific in every respect
Posted in Uncategorized | Leave a Comment »
Reprogramming Normal Cell Lines into Stem-like Cells
Reporter: Aviva Lev-Ari, PhD, RN
More information: “Actin stress in cell reprogramming.” PNAS 2014 111 (49) E5252-E5261; published ahead of print November 24, 2014, DOI: 10.1073/pnas.1411683111
Read more at: http://phys.org/news/2014-12-mechanical-cues-reprogram-cell-lines.html#jCp
and
http://phys.org/news/2014-12-mechanical-cues-reprogram-cell-lines.html
Mechanical cues reprogram normal cell lines into stem-like cells
Dec 11, 2014 by Ellen Goldbaum
Scientists at the University at Buffalo and other institutions have turned cells normally used as model cells, known as immortalized cells, into stem or, as they call it, “stem-like” cells, using nothing more than mechanical stress. They have done it without employing the potentially hazardous techniques previously used to obtain similar results.
The finding is described in a paper published recently online before print in the Proceedings of the National Academy of Sciences. The researchers discovered that by changing the mechanical stresses on neuronal and other cell types in tissue culture allowed them to be reprogrammed into “stem-like” cells.
“Normal cell types in tissue culture are spread out and have differentiated internal structures, but changing cell mechanics caused the cells to turn into clusters of spherical cells that had many of the biochemical markers of cells,” says Frederick Sachs, PhD, SUNY Distinguished Professor in the UB Department of Physiology and Biophysics and senior author.
Read more at: http://phys.org/news/2014-12-mechanical-cues-reprogram-cell-lines.html#jCp
Posted in Stem Cells for Regenerative Medicine | Leave a Comment »
Biologically Distinct Breast Cancer Subtypes: The Role of Epigenetics
Reporter: Aviva Lev-Ari, PhD, RN
Article reference
A DNA methylation-based definition of biologically distinct breast cancer subtypes. Stefansson OA, Moran S, Gomez A, Sayols S, Arribas-Jorba C, Sandoval J, Hilmarsdottir H, Ólafsdóttir I, Tryggvadottir L, Jonasson JG, Eyfjord J, Esteller M. Molecular Oncology, PII: S1574-7891 (14) 00261 -0, 2014.
Mol Oncol. 2014 Nov 5. pii: S1574-7891(14)00261-0. doi: 10.1016/j.molonc.2014.10.012. [Epub ahead of print]
A DNA methylation-based definition of biologically distinct breast cancer subtypes.
Stefansson OA1, Moran S1, Gomez A1, Sayols S1, Arribas-Jorba C1, Sandoval J1, Hilmarsdottir H2, Olafsdottir E3, Tryggvadottir L3, Jonasson JG4,Eyfjord J2, Esteller M5.
Abstract
In cancer, epigenetic states are deregulated and thought to be of significance in cancer development and progression. We explored DNA methylation-based signatures in association with breast cancer subtypes to assess their impact on clinical presentation and patient prognosis. DNA methylation was analyzed using Infinium 450K arrays in 40 tumors and 17 normal breast samples, together with DNA copy number changes and subtype-specific markers by tissue microarrays. The identified methylation signatures were validated against a cohort of 212 tumors annotated for breast cancer subtypes by the PAM50 method (The Cancer Genome Atlas). Selected markers were pyrosequenced in an independent validation cohort of 310 tumors and analyzed with respect to survival, clinical stage and grade. The results demonstrate that DNA methylation patterns linked to the luminal-B subtype are characterized by CpG island promoter methylation events. In contrast, a large fraction of basal-like tumors are characterized by hypomethylation events occurring within the gene body. Based on these hallmark signatures, we defined two DNA methylation-based subtypes, Epi-LumB and Epi-Basal, and show that they are associated with unfavorable clinical parameters and reduced survival. Our data show that distinct mechanisms leading to changes in CpG methylation states are operative in different breast cancer subtypes. Importantly, we show that a few selected proxy markers can be used to detect the distinct DNA methylation-based subtypes thereby providing valuable information on disease prognosis.
NEW BREAST CANCER CLASSIFICATION BASED ON EPIGENETICS.

Statistics from The Breast Cancer Research Foundation state that nearly 1.7 million new breast cancer cases were diagnosed in 2012. Breast cancer is the second most common cancer in women and men worldwide. In 2012, it represented about 12 percent of all new cancer cases and 25 percent of all cancers in women. Breast cancer is the most frequently diagnosed cancer among women in 140 of 184 countries worldwide.
Globally, breast cancer now represents one in four of all cancers in women. Progress in prevention and early detection, and the use of chemotherapy after surgery (adjuvant chemotherapy), have achieved significantly increase survival in this disease in the last ten years, but much remains to be done.
The identification of patients with high-risk breast cancer is key to knowing whether a patient will require only the removal of the tumour by surgery or whether if they will need additional chemotherapy to make sure the removal of breast cancer cells. Currently, known genetic mutations and expression patterns are determined, but the puzzle of the genetics of the disease remains a large unfinished part.
To address this the researchers analyzed epigenetic alterations, namely the chemical signal called DNA methylation in 500 breast tumours and have compared the patterns obtained with the clinical behaviour of these cancers.
The team note that there are two subgroups of breast tumours by epigenome; one which they have named Epi-Basal, characterized by loss of epigenetic marks causing breakage of chromosomes and the other that the researchers have called Epi-Luminal B, that presents epigenetic inactivation of genes that should protect humans from cancer and the altered cells that can no longer do it.
The researchers highlight that the subtype Epi-Luminal B behaves particularly aggressive form, and is associated with reduced survival of patients. They would therefore recommend that with this class of tumour the medical team avoid surgery and instead administer adjuvant chemotherapy and in those tumours with a more ‘benign’ epigenetic pattern; surgery alone may be curative, thus avoiding the side effects of chemotherapy.
Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Genomic Expression | Leave a Comment »
“@smithECGBlog: A Hybrid of de Winter’s T-waves and Diffuse Subendocardial Ischemia: #FOAMed http://t.co/IBTUwRX5KE http://t.co/LSFDBp1ipa”
Source: hqmeded-ecg.blogspot.fr
Posted in Uncategorized | Leave a Comment »






